833. Efficacy and Safety of Long-Acting Cabotegravir + Rilpivirine in Participants with HIV/HCV Co-infection: ATLAS-2M 48-Week Results

por D’Amico, Ronald, Benn, Paul, Thiagarajah, Shanker, Ford, Susan L, Birmingham, Eileen, Upadhyay, Ojesh R, Garside, Louise, Van Solingen-Ristea, Rodica, Vandermeulen, Kati, Spreen, William
Publicado 2021

885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials

por Patel, Parul, Ford, Susan L, Baker, Mark, Meyer, Claudia, Garside, Louise, D’Amico, Ronald, Van Solingen-Ristea, Rodica, Crauwels, Herta, Polli, Joseph, Seal, Ciara, Thiagarajah, Shanker, Birmingham, Eileen, Spreen, William, Baugh, Bryan, Bosse, Matthew, Vannappagari, Vani
Publicado 2021

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Lab...

por Overton, Edgar T, Richmond, Gary, Rizzardini, Giuliano, Thalme, Anders, Girard, Pierre-Marie, Wong, Alexander, Porteiro, Norma, Swindells, Susan, Reynes, Jacques, Noe, Sebastian, Harrington, Conn, Español, Carlos Martín, Acuipil, Carolina, Aksar, Asma, Wang, Yuanyuan, Ford, Susan L, Crauwels, Herta, van Eygen, Veerle, Van Solingen-Ristea, Rodica, Latham, Christine L, Thiagarajah, Shanker, D’Amico, Ronald, Smith, Kimberly Y, Vandermeulen, Kati, Spreen, William R
Publicado 2023